Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novelos Therapeutics is to collaborate with Shriners Hospitals for Children to confirm positive preclinical findings of its investigational compound NOV-002 in the therapy of acute radiation injury.
Subscribe to our email newsletter
Novelos plans to submit a proposal to the Department of Health and Human Services (DHHS) in 2006 for treatment of patients with NOV-002 after acute exposure to lethal radiation.
In previous preclinical experiments conducted in Russia, groups of mice and rats were exposed to lethal doses of radiation. The treatment of animals with NOV-002 (after irradiation) resulted in a two- to three-fold increase in thirty day survival compared to the irradiated but untreated control animals.
NOV-002 treated animals did not experience severe neutropenia (loss of white blood cells used for fighting off infections) and demonstrated significantly higher bone marrow cell counts than the control (bone marrow is the source of white blood cells).
“In addition to confirming and extending these findings, our research collaboration with Shriners Hospital, a leading medical research institution, aims to more precisely identify the cellular and molecular actions of NOV-002 that underlie its ability to combat acute radiation injury,” said Dr Christopher Pazoles, vice president of R&D of Novelos Therapeutics.
NOV-002 is also being developed to treat ovarian cancer that is not responsive to chemotherapy.